366 related articles for article (PubMed ID: 18450313)
1. Preparation and characterization of PE38KDEL-loaded anti-HER2 nanoparticles for targeted cancer therapy.
Chen H; Gao J; Lu Y; Kou G; Zhang H; Fan L; Sun Z; Guo Y; Zhong Y
J Control Release; 2008 Jun; 128(3):209-16. PubMed ID: 18450313
[TBL] [Abstract][Full Text] [Related]
2. PE38KDEL-loaded anti-HER2 nanoparticles inhibit breast tumor progression with reduced toxicity and immunogenicity.
Gao J; Kou G; Wang H; Chen H; Li B; Lu Y; Zhang D; Wang S; Hou S; Qian W; Dai J; Zhao J; Zhong Y; Guo Y
Breast Cancer Res Treat; 2009 May; 115(1):29-41. PubMed ID: 18481173
[TBL] [Abstract][Full Text] [Related]
3. Tumor-targeted PE38KDEL delivery via PEGylated anti-HER2 immunoliposomes.
Gao J; Zhong W; He J; Li H; Zhang H; Zhou G; Li B; Lu Y; Zou H; Kou G; Zhang D; Wang H; Guo Y; Zhong Y
Int J Pharm; 2009 Jun; 374(1-2):145-52. PubMed ID: 19446771
[TBL] [Abstract][Full Text] [Related]
4. Treatment of hepatocellular carcinoma in mice with PE38KDEL type I mutant-loaded poly(lactic-co-glycolic acid) nanoparticles conjugated with humanized SM5-1 F(ab') fragments.
Gao J; Kou G; Chen H; Wang H; Li B; Lu Y; Zhang D; Wang S; Hou S; Qian W; Dai J; Zhao J; Zhong Y; Guo Y
Mol Cancer Ther; 2008 Oct; 7(10):3399-407. PubMed ID: 18852143
[TBL] [Abstract][Full Text] [Related]
5. Pseudomonas exotoxin-based immunotoxins containing the antibody LL2 or LL2-Fab' induce regression of subcutaneous human B-cell lymphoma in mice.
Kreitman RJ; Hansen HJ; Jones AL; FitzGerald DJ; Goldenberg DM; Pastan I
Cancer Res; 1993 Feb; 53(4):819-25. PubMed ID: 8428363
[TBL] [Abstract][Full Text] [Related]
6. A chemical conjugate between HER2-targeting antibody fragment and Pseudomonas exotoxin A fragment demonstrates cytotoxic effects on HER2-expressing breast cancer cells.
Lee S; Park S; Nguyen MT; Lee E; Kim J; Baek S; Kim CJ; Jang YJ; Choe H
BMB Rep; 2019 Aug; 52(8):496-501. PubMed ID: 30670149
[TBL] [Abstract][Full Text] [Related]
7. Designing the furin-cleavable linker in recombinant immunotoxins based on Pseudomonas exotoxin A.
Weldon JE; Skarzynski M; Therres JA; Ostovitz JR; Zhou H; Kreitman RJ; Pastan I
Bioconjug Chem; 2015 Jun; 26(6):1120-8. PubMed ID: 25997032
[TBL] [Abstract][Full Text] [Related]
8. Protection of the Furin Cleavage Site in Low-Toxicity Immunotoxins Based on Pseudomonas Exotoxin A.
Kaplan G; Lee F; Onda M; Kolyvas E; Bhardwaj G; Baker D; Pastan I
Toxins (Basel); 2016 Jul; 8(8):. PubMed ID: 27463727
[TBL] [Abstract][Full Text] [Related]
9. Improved binding and antitumor activity of a recombinant anti-erbB2 immunotoxin by disulfide stabilization of the Fv fragment.
Reiter Y; Brinkmann U; Jung SH; Lee B; Kasprzyk PG; King CR; Pastan I
J Biol Chem; 1994 Jul; 269(28):18327-31. PubMed ID: 7913461
[TBL] [Abstract][Full Text] [Related]
10. B3(Fab)-PE38M: a recombinant immunotoxin in which a mutant form of Pseudomonas exotoxin is fused to the Fab fragment of monoclonal antibody B3.
Choe M; Webber KO; Pastan I
Cancer Res; 1994 Jul; 54(13):3460-7. PubMed ID: 8012967
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxic and antitumor activity of a recombinant immunotoxin composed of disulfide-stabilized anti-Tac Fv fragment and truncated Pseudomonas exotoxin.
Reiter Y; Kreitman RJ; Brinkmann U; Pastan I
Int J Cancer; 1994 Jul; 58(1):142-9. PubMed ID: 8014011
[TBL] [Abstract][Full Text] [Related]
12. Modular Conjugation of a Potent Anti-HER2 Immunotoxin Using Coassociating Peptides.
Stoessel A; Groysbeck N; Guyot L; Barret L; Nominé Y; Nguekeu-Zebaze L; Bender A; Voilquin L; Lutz T; Pallaoro N; Blocat M; Deville C; Masson M; Zuber G; Chatton B; Donzeau M
Bioconjug Chem; 2020 Oct; 31(10):2421-2430. PubMed ID: 32996763
[TBL] [Abstract][Full Text] [Related]
13. Recombinant immunotoxin containing a disulfide-stabilized Fv directed at erbB2 that does not require proteolytic activation.
Kuan CT; Pastan I
Biochemistry; 1996 Mar; 35(9):2872-7. PubMed ID: 8608123
[TBL] [Abstract][Full Text] [Related]
14. A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific single-chain antibody fragment has potent and selective antitumor activity.
Di Paolo C; Willuda J; Kubetzko S; Lauffer I; Tschudi D; Waibel R; Plückthun A; Stahel RA; Zangemeister-Wittke U
Clin Cancer Res; 2003 Jul; 9(7):2837-48. PubMed ID: 12855664
[TBL] [Abstract][Full Text] [Related]
15. Recombinant anti-erbB2 immunotoxins containing Pseudomonas exotoxin.
Batra JK; Kasprzyk PG; Bird RE; Pastan I; King CR
Proc Natl Acad Sci U S A; 1992 Jul; 89(13):5867-71. PubMed ID: 1352878
[TBL] [Abstract][Full Text] [Related]
16. Preparation and characterization of fusion protein truncated Pseudomonas Exotoxin A (PE38KDEL) in Escherichia coli.
Song S; Xue J; Fan K; Kou G; Zhou Q; Wang H; Guo Y
Protein Expr Purif; 2005 Nov; 44(1):52-7. PubMed ID: 15922623
[TBL] [Abstract][Full Text] [Related]
17. Investigation of antitumor activities of trastuzumab delivered by PLGA nanoparticles.
Colzani B; Pandolfi L; Hoti A; Iovene PA; Natalello A; Avvakumova S; Colombo M; Prosperi D
Int J Nanomedicine; 2018; 13():957-973. PubMed ID: 29491709
[TBL] [Abstract][Full Text] [Related]
18. Construction, expression, and characterization of an anti-tumor immunotoxin containing the human anti-c-Met single-chain antibody and PE38KDEL.
Liu Z; Feng Z; Zhu X; Xu W; Zhu J; Zhang X; Fan Z; Ji G
Immunol Lett; 2013 Jan; 149(1-2):30-40. PubMed ID: 23026237
[TBL] [Abstract][Full Text] [Related]
19. Humanized CD7 nanobody-based immunotoxins exhibit promising anti-T-cell acute lymphoblastic leukemia potential.
Yu Y; Li J; Zhu X; Tang X; Bao Y; Sun X; Huang Y; Tian F; Liu X; Yang L
Int J Nanomedicine; 2017; 12():1969-1983. PubMed ID: 28331319
[TBL] [Abstract][Full Text] [Related]
20. Increased antitumor activity of a circularly permuted interleukin 4-toxin in mice with interleukin 4 receptor-bearing human carcinoma.
Kreitman RJ; Puri RK; Pastan I
Cancer Res; 1995 Aug; 55(15):3357-63. PubMed ID: 7614471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
